BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21295855)

  • 21. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
    Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
    J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.
    Liu H; Seijsing J; Frejd FY; Tolmachev V; Gräslund T
    Int J Oncol; 2015 Aug; 47(2):601-9. PubMed ID: 26046132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth.
    Behdani M; Zeinali S; Karimipour M; Khanahmad H; Schoonooghe S; Aslemarz A; Seyed N; Moazami-Godarzi R; Baniahmad F; Habibi-Anbouhi M; Hassanzadeh-Ghassabeh G; Muyldermans S
    N Biotechnol; 2013 Jan; 30(2):205-9. PubMed ID: 23031816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting malignant B cells with an immunotoxin against ROR1.
    Baskar S; Wiestner A; Wilson WH; Pastan I; Rader C
    MAbs; 2012; 4(3):349-61. PubMed ID: 22531447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ezrin is a key molecule in the metastasis of MOLT4 cells induced by CCL25/CCR9.
    Zhou B; Leng J; Hu M; Zhang L; Wang Z; Liu D; Tong X; Yu B; Hu Y; Deng C; Liu Y; Zhang Q
    Leuk Res; 2010 Jun; 34(6):769-76. PubMed ID: 20036004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
    Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
    Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Turn a diarrhoea toxin into a receptor-mediated therapy for a plethora of CLDN-4-overexpressing cancers.
    Yao Q; Cao S; Li C; Mengesha A; Low P; Kong B; Dai S; Wei M
    Biochem Biophys Res Commun; 2010 Jul; 398(3):413-9. PubMed ID: 20599713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.
    Bauss F; Lechmann M; Krippendorff BF; Staack R; Herting F; Festag M; Imhof-Jung S; Hesse F; Pompiati M; Kollmorgen G; da Silva Mateus Seidl R; Bossenmaier B; Lau W; Schantz C; Stracke JO; Brinkmann U; Onda M; Pastan I; Bosslet K; Niederfellner G
    Mol Oncol; 2016 Oct; 10(8):1317-29. PubMed ID: 27507537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cintredekin besudotox in treatment of malignant glioma.
    Mut M; Sherman JH; Shaffrey ME; Schiff D
    Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.
    Stish BJ; Oh S; Chen H; Dudek AZ; Kratzke RA; Vallera DA
    Br J Cancer; 2009 Oct; 101(7):1114-23. PubMed ID: 19755995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lectin drug conjugate therapy for colorectal cancer.
    Kitaguchi D; Oda T; Enomoto T; Ohara Y; Owada Y; Akashi Y; Furuta T; Yu Y; Kimura S; Kuroda Y; Kurimori K; Miyazaki Y; Furuya K; Shimomura O; Tateno H
    Cancer Sci; 2020 Dec; 111(12):4548-4557. PubMed ID: 33058342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
    Weldon JE; Skarzynski M; Therres JA; Ostovitz JR; Zhou H; Kreitman RJ; Pastan I
    Bioconjug Chem; 2015 Jun; 26(6):1120-8. PubMed ID: 25997032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.
    Vallera DA; Oh S; Chen H; Shu Y; Frankel AE
    Mol Cancer Ther; 2010 Jun; 9(6):1872-83. PubMed ID: 20530709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of livin activation.
    Qiuping Z; Jei X; Youxin J; Wei J; Chun L; Jin W; Qun W; Yan L; Chunsong H; Mingzhen Y; Qingping G; Kejian Z; Zhimin S; Qun L; Junyan L; Jinquan T
    Cancer Res; 2004 Oct; 64(20):7579-87. PubMed ID: 15492285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer.
    Fischer A; Wolf I; Fuchs H; Masilamani AP; Wolf P
    Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33260619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties.
    Kawakami K; Nakajima O; Morishita R; Nagai R
    ScientificWorldJournal; 2006 Jul; 6():781-90. PubMed ID: 16830050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
    Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
    Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.
    Wolf P; Alt K; Bühler P; Katzenwadel A; Wetterauer U; Tacke M; Elsässer-Beile U
    Prostate; 2008 Feb; 68(2):129-38. PubMed ID: 18044731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.
    Kaplan G; Lee F; Onda M; Kolyvas E; Bhardwaj G; Baker D; Pastan I
    Toxins (Basel); 2016 Jul; 8(8):. PubMed ID: 27463727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway.
    Li B; Wang Z; Zhong Y; Lan J; Li X; Lin H
    Med Oncol; 2015 Mar; 32(3):66. PubMed ID: 25691296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.